Prospect Capital's portfolio continues to show weakness in a high interest rate environment, leading to a 23% price drop over the last year and a slight dividend reduction. Despite a high dividend yield of 13%, PSEC's total return is negative, and it trades at a significant discount to NAV due to underlying weaknesses. PSEC's earnings have declined, with net investment income at its lowest levels since 2021 and NAV decreasing by 12.1% over the past year.

IPGP struggles with declining material processing and medical sales, but growth in advanced applications sparks optimism.

BOH, AUB, BHRB, IMTX and RH have been added to the Zacks Rank #1 (Strong Buy) List on February 12, 2025.

Shares of tech giant Broadcom Inc. NASDAQ: AVGO have been a joy for investors to hold, delivering a massive 130% gain in 2024 that included an all-time high in December. It would have been a shock for them when the rally came to an abrupt halt last month after a DeepSeek-driven selloff saw the stock shed 20% in just a matter of sessions.

SUNNYVALE, Calif.--(BUSINESS WIRE)--Juniper Networks, (NYSE: JNPR), a leader in secure, AI-Native Networking, today announced new additions to its leading wired access portfolio that enable companies of all sizes to scale their IT operations, proactively mitigate risks and successfully facilitate strategic digital transformation initiatives. Designed from the ground up to sustainably support modern wired and wireless access needs, the new Juniper Networks® EX4000 Series Switches leverage a grou.

Omnicell's Q4 2024 earnings showed strong service revenue growth, despite soft overall revenue guidance, highlighting the service business as the key value driver. My updated DCF analysis yields a price target of $64.05, representing a 54% upside, and I raise my rating from buy to strong buy. The service business has grown from 6% to 22% of revenue since 2020, outpacing industry growth and improving margins, indicating long-term value.

MALVERN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that dosing is complete, ahead of schedule in the Phase 2 portion of the Phase 1/2 ArMaDa clinical trial for OCU410—a novel multifunctional modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). Age-related macular degeneration (AMD) affects 1 in 8 people 60 years and older. The global prevalence of dAMD is 266 million worldwide and …

SÃO PAULO, Feb. 12, 2025 /PRNewswire/ -- Embraer S.A. ("Embraer") (NYSE: ERJ) announces the expiration of its previously announced offer to purchase for cash any and all outstanding 5.400% senior unsecured guaranteed notes due 2027 (the "2027 Notes") issued by Embraer Netherlands Finance B.V.

Generac reported fourth-quarter earnings per share of $2.80 from sales of $1.2 billion on Wednesday. Wall Street was looking for $2.53 and $1.2 billion, respectively.

It's no big secret that Warren Buffett has been a net seller of stocks recently. Thanks to several massive stock sales, and a few smaller ones, Berkshire Hathaway's (BRK.A 0.50%) (BRK.B 0.52%) cash stockpile has ballooned to $325 billion as of the most recent quarter, far more than the conglomerate has ever had on hand before.

PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts.

The artificial-intelligence lending platform expects first-quarter revenue of about $200 million, better than estimates of $184.6 million.

Income should pour into your account, not dribble in. We take a three-legged approach to mREIT investing for income. Today, we dive into the third leg.

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments

NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's proprietary technology.

Meta Platforms (NASDAQ: META) has extended its historic rally, closing higher for the 17th consecutive session and marking its longest winning streak ever. The stock has surged 18% during this run and is now up 22% year-to-date, closing at $719.80 on February 11.

TruBridge (TBRG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Oil futures fell Wednesday, threatening to end a three-day winning streak, after industry data showed a large rise in U.S. crude inventories.

Retail investors can really benefit from following the recent developments coming out of Wall Street, especially during volatile market times like these, which President Trump's recent trade tariffs have sparked. In all the uncertainty about what might happen to the United States economy, markets have lost track of what's essential.

I once thought holding cash for a market crash was smart, but waiting for crashes is a risky game. Inflation devalues cash much faster than investing. Market timing is tough. Predicting corrections consistently is nearly impossible, and staying invested can prevent the damage inflation causes to your purchasing power. Instead of waiting for the "perfect" moment, I focus on consistent investing in resilient infrastructure and public real estate that outperforms the market.